Improvements in Neurocognitive Function and Mood Following Adjunctive Treatment with Mifepristone (RU-486) in Bipolar Disorder
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
High cortisol levels are found in severe mood disorders, particularly bipolar disorder. Hypercortisolaemia may cause or exacerbate both neurocognitive impairment and depressive symptoms. We hypothesized that antiglucocorticoid treatments, particularly corticosteroid receptor antagonists, would improve neurocognitive functioning and attenuate depressive symptoms in this disorder. To test this hypothesis, 20 bipolar patients were treated with 600 mg/day of the corticosteroid receptor antagonist mifepristone (RU-486) or placebo for 1 week in a double-blind crossover design. Over the total 6 weeks of the study, neurocognitive and neuroendocrine function were evaluated at baseline, days 21 and 42. Mood symptoms were evaluated weekly. Nineteen subjects completed the protocol; there were no drop-outs due to adverse events. Following treatment with mifepristone, selective improvement in neurocognitive functioning was observed. Spatial working memory performance was significantly improved compared to placebo (19.8% improvement over placebo). Measures of verbal fluency and spatial recognition memory were also improved after mifepristone. Beneficial effects on mood were found; Hamilton Depression Rating Scale scores were significantly reduced compared to baseline (mean reduction of 5.1 points) as were Montgomery-Asberg Depression Rating Scale scores (mean reduction of 6.05 points). No significant change occurred after placebo. These data require replication but provide preliminary evidence that glucocorticoid receptor antagonists may have useful cognitive-enhancing and possibly antidepressant properties in bipolar disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“drugs targeting the HPA axis can improve BD symptoms (Young et al. 2004;Young ,2014;Juruena et al. 2009).”
From The HPA axis in bipolar disorder: Systematic review and meta-analysis (2016) · cites this paper as Young et al. 2004
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 3×
“…symptomatic improvement, the antidepressant effect of mifepristone was the principal focus, therefore the outcome measures of interest were the 17-item Hamilton Depression Rating Scale (HDRS17; Hamilton, 1960) and the Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979).”
MethodInfluentialA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 3×
“…symptomatic improvement, the antidepressant effect of mifepristone was the principal focus, therefore the outcome measures of interest were the 17-item Hamilton Depression Rating Scale (HDRS17; Hamilton, 1960) and the Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979).”
MethodInfluentialKessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370 · cited 1×
“Bipolar disorder is a chronic and recurrent illness, with a lifetime incidence of at least 1% (Kessler et al, 1994).”
BackgroundThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 1×
“Other secondary scales consisted of the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962) and the Young Mania Rating Scale (YMRS; Young et al, 1978).”
MethodA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“Other secondary scales consisted of the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962) and the Young Mania Rating Scale (YMRS; Young et al, 1978).”
MethodNeuropsychological assessment.
Cipolotti, L., & Warrington, E. K. (1995) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.58.6.655 · Cited by 3,234
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106 · cited 1×
“Although the illness is defined by the occurrence of mania, the depressed phase predominates (Judd et al, 2002, 2003) and represents the greatest therapeutic challenge.”
BackgroundGlucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016 · cited 2×
“It has been suggested that abnormalities in hypothalamic–pituitary– adrenal (HPA) axis function may cause or exacerbate both neurocognitive impairment and depressive symptoms (McQuade and Young, 2000; Sapolsky, 2000).”
BackgroundSmithson, M. (2000) · SAGE Publications Ltd eBooks · doi:10.4135/9781446218525 · Cited by 1,871
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243 · cited 1×
“Although the illness is defined by the occurrence of mania, the depressed phase predominates (Judd et al, 2002, 2003) and represents the greatest therapeutic challenge.”
Background
Research works printed but not linked: 5
- Cegalis J, Bowlin J (1991). Vigil: Software for the Assessment of Attention. Forthought: Nashua, NH.
- First MB, Spitzer RL, Williams JBW, Gibbon M (1995). Structured Clinical Interview for DSM-IV (SCID-I), Research Version. Biometrics Research Department, New York State Psychiatric Institute: New York.
- Høyberg ØJ, Wik G, Mehtonen OP, Peeters BWMM, Sennef C (2002). ORG 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: first clinical results. Int J Neuropsychopharmacol 5: S148.
- Lopez JF, Little KY, Lopez-Figueroa AL, Lopez-Figueroa MO, Watson SJ (2003). Glucocorticoid and mineralocorticoid receptor mRNA levels in the hippocampus and prefrontal cortex of subjects with mood disorders and schizophrenia. Biol Psychiatry 53: 489.
- Thompson JM, Gray JM, Hughes J, Watson S, Ferrier I, Young AH (2000). A component process analysis of working memory dysfunction in bipolar affective disorder. J Psychopharmacol (Oxf) 14: A24.
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Keller, J., Gomez, R., Williams, G., Lembke, A., Lazzeroni, L., Murphy, G. M., & Schatzberg, A. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.120 · Cited by 922
“In addition, Young's group reported that the GR antagonist mifepristone significantly improves visual memory in bipolar depression (31).”
BackgroundThe glucocorticoid receptor: Pivot of depression and of antidepressant treatment?
Anacker, C., Zunszain, P. A., Carvalho, L. A., & Pariante, C. M. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.03.007 · Cited by 592
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats
Aisa, B., Tordera, R., Lasheras, B., Del Río, J., & Ramírez, M. J. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2006.12.013 · Cited by 539
“In addition, preliminary clinical evidence has been provided that glucocorticoid receptor antagonist may have useful cognitive-enhancing properties in bipolar disorder (Young et al., 2004).”
BackgroundRobinson, L. J., & Nicol Ferrier, I. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00277.x · Cited by 531
Allostatic load in bipolar disorder: Implications for pathophysiology and treatment
Kapczinski, F., Vieta, E., Andreazza, A. C., Frey, B. N., Gomes, F. A., Tramontina, J., Kauer-Sant’Anna, M., Grassi-Oliveira, R., & Post, R. M. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.10.005 · Cited by 480
Unravelling the pathophysiology of delirium: A focus on the role of aberrant stress responses
MacLullich, A. M. J., Ferguson, K. J., Miller, T., de Rooij, S. E. J. A., & Cunningham, C. (2008) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2008.05.019 · Cited by 447
“Blockade of GR has also been found to improve performance on prefrontal– cortical tasks in patients with bipolar illness [82].”
BackgroundThe HPA axis in bipolar disorder: Systematic review and meta-analysis
Belvederi Murri, M., Prestia, D., Mondelli, V., Pariante, C., Patti, S., Olivieri, B., Arzani, C., Masotti, M., Respino, M., Antonioli, M., et al. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.10.014 · Cited by 391
“, 2012); (5) drugs tareting the HPA axis can improve BD symptoms (Young et al., 2004; oung, 2014; Juruena et al., 2009).”
BackgroundAnxiety selectively disrupts visuospatial working memory
Shackman, A. J., Sarinopoulos, I., Maxwell, J. S., Pizzagalli, D. A., Lavric, A., & Davidson, R. J. (2006) · Emotion · doi:10.1037/1528-3542.6.1.40 · Cited by 382
“Manipulations of catecholamines (Luciana & Collins, 1997) and cortisol (e.g., Young et al., 1999, 2004) disproportionately impact the performance of spatial relative to verbal tasks.”
BackgroundJohnson, S. A., Fournier, N. M., & Kalynchuk, L. E. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.11.019 · Cited by 340
Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies
Solé, B., Jiménez, E., Torrent, C., Reinares, M., Bonnin, C. D. M., Torres, I., Varo, C., Grande, I., Valls, E., Salagre, E., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx032 · Cited by 299
“Mifepristone, a corticosteroid receptor antagonist, showed preliminary evidence to improve spatial working memory in depressed bipolar patients in 2 studies, the enhancement occurring in the absence of an improvement in depressed mood (Young et al., 2004; Watson et al., 2012).”
BackgroundNeurocognitive impairment in bipolar disorder patients: functional implications
Wingo, A. P., Harvey, P. D., & Baldessarini, R. J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00665.x · Cited by 274
Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder
Zarate, C. A., Singh, J., & Manji, H. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.021 · Cited by 274
The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I. D., Salvadore, G., & Zarate, C. A. (2010) · Pharmaceuticals · doi:10.3390/ph3010019 · Cited by 263
“In a six-week trial in individuals with bipolar depression, mifepristone (600 mg/day) improved depressive symptoms and cognitive functioning compared to placebo [84].”
BackgroundGlucocorticoid receptor overexpression in forebrain: A mouse model of increased emotional lability
Wei, Q., Lu, X.-Y., Liu, L., Schafer, G., Shieh, K.-R., Burke, S., Robinson, T. E., Watson, S. J., Seasholtz, A. F., & Akil, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402208101 · Cited by 248
Self-citationCognitive deficits in bipolar disorders: Implications for emotion
Lima, I. M. M., Peckham, A. D., & Johnson, S. L. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.11.006 · Cited by 250
“For example, cognition has been found to improve with treatment lamotrigine (Pavuluri, Passarotti, Mohammed, Carbray, & Sweeney, 2010) or mifepristone (Young et al., 2004) in BD.”
BackgroundHypothalamic-pituitary-adrenal axis and bipolar disorder
Daban, C., Vieta, E., Mackin, P., & Young, A. H. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2005.01.005 · Cited by 245
“The first preliminary double-blind, placebo-controlled, crossover study examining the effects of mifepristone (600 mg/day for 7 days) in 20 patients with bipolar disorder has been recently completed [57].”
BackgroundSelf-citationCognitive Impairment in Major Depression: Association with Salivary Cortisol
Hinkelmann, K., Moritz, S., Botzenhardt, J., Riedesel, K., Wiedemann, K., Kellner, M., & Otte, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.06.023 · Cited by 216
Neuropsychological Impairment in Major Depression: Its Nature, Origin and Clinical Significance
Porter, R. J., Bourke, C., & Gallagher, P. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601109881 · Cited by 236
Self-citationPhillips, L. J., Mcgorry, P. D., Garner, B., Thompson, K. N., Pantelis, C., Wood, S. J., & Berger, G. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01877.x · Cited by 228
“This was surprising to the researchers as an earlier study in bipolar patients had shown an ameliorative effect of RU486 on neurocognitive functioning [112].”
ResultMiskowiak, K., Burdick, K., Martinez‐Aran, A., Bonnin, C., Bowie, C., Carvalho, A., Gallagher, P., Lafer, B., López‐Jaramillo, C., Sumiyoshi, T., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12534 · Cited by 216
Self-citationMiskowiak, K., Burdick, K., Martinez‐Aran, A., Bonnin, C., Bowie, C., Carvalho, A., Gallagher, P., Lafer, B., López‐Jaramillo, C., Sumiyoshi, T., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12595 · Cited by 213
Self-citationLongitudinal Assessment of Neuropsychological Function in Major Depression
Douglas, K. M., & Porter, R. J. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048670903279887 · Cited by 217
“Only one study specifi cally examined bipolar depression [8], while remaining studies that included bipolar depressed patients did not separate the analysis into subtypes, meaning that it cannot be determined whether there are different neuropsychological changes over time between unipolar and bipolar depression.”
BackgroundResultAisa, B., Tordera, R., Lasheras, B., Del Río, J., & Ramírez, M. J. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.05.011 · Cited by 206
Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300884 · Cited by 203
“…studies by our group have shown significant reduction of psychotic symptoms in some patients treated with mifepristone (Belanoff et al, 2001, 2002), and a study by Young et al (2004) reported that the drug rapidly resulted in improved cognition (verbal memory) in nonpsychotic bipolar depressives.”
Backgroundde Kloet, E. R., DeRijk, R. H., & Meijer, O. C. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0403 · Cited by 193
Xu, G., Lin, K., Rao, D., Dang, Y., Ouyang, H., Guo, Y., Ma, J., & Chen, J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.11.029 · Cited by 182
“In contrast with many studies (Reppermund et al., 2009; Young et al., 2004), our result found that verbal fluency was not improved to normal after recovery from depression.”
ResultThe glucocorticoid receptor: part of the solution or part of the problem?
Pariante, C. M. (2006) · Journal of Psychopharmacology · doi:10.1177/1359786806066063 · Cited by 192
Pariante, C. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04978.x · Cited by 181
Mayer, J. L., Klumpers, L., Maslam, S., De Kloet, E. R., Joëls, M., & Lucassen, P. J. (2006) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01455.x · Cited by 181
Butts, K. A., Weinberg, J., Young, A. H., & Phillips, A. G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111746108 · Cited by 182
“Limited duration of treatment with GR antagonists may be warranted, given our observation of improved neurocognitive function following 7 d of adjunctive treatment with RU-38486 in patients with bipolar disorder (48).”
BackgroundSelf-citationIdentifying and treating cognitive impairment in bipolar disorder
Goldberg, J. F., & Roy Chengappa, K. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00716.x · Cited by 174
Green tea polyphenols produce antidepressant-like effects in adult mice
Zhu, W.-L., Shi, H.-S., Wei, Y.-M., Wang, S.-J., Sun, C.-Y., Ding, Z.-B., & Lu, L. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.007 · Cited by 175
Rosenblat, J. D., Brietzke, E., Mansur, R. B., Maruschak, N. A., Lee, Y., & McIntyre, R. S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.08.058 · Cited by 172
Effects of chronic stress on cognitive function – From neurobiology to intervention
Girotti, M., Bulin, S. E., & Carreno, F. R. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100670 · Cited by 210
“Indeed, several pharmacological studies with agonists and antagonists of GR and MR have revealed the importance of each receptor in cognitive function (Otte et al., 2007; Piber et al., 2016; Vogel et al., 2016; Wingenfeld and Otte 2019; Yalin et al., 2021; Young et al., 2004).”
DeBattista, C., Belanoff, J., Glass, S., Khan, A., Horne, R. L., Blasey, C., Carpenter, L. L., & Alva, G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.034 · Cited by 162
Cognition and disability in bipolar disorder: lessons from schizophrenia research
Harvey, P. D., Wingo, A. P., Burdick, K. E., & Baldessarini, R. J. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00831.x · Cited by 159
Innovative Approaches for the Treatment of Depression: Targeting the HPA Axis
THOMSON, F. J., & Craighead, M. W. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9518-3 · Cited by 171
Hypothalamic‐Pituitary‐Adrenocortical Axis: Neuropsychiatric Aspects
Jacobson, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130036 · Cited by 144
Glucocorticoid Receptor Function In Vitro in Patients with Major Depression
Pariante, C. M. (2004) · Stress · doi:10.1080/10253890500069650 · Cited by 147
“On the other side, surprisingly, GR antagonists, like RU486, have therapeutic effects in the treatment of psychotic depression (Belanoff et al., 2001) and bipolar disorder (Young et al., 2004).”
BackgroundPharmacological approaches in bipolar disorders and the impact on cognition: a critical overview
Dias, V. V., Balanzá‐Martinez, V., Soeiro‐de‐Souza, M. G., Moreno, R. A., Figueira, M. L., Machado‐Vieira, R., & Vieta, E. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01910.x · Cited by 146
“Given benzodiazepines are not currently described as potential therapeutic approach in BD and buspirone has been recently proposed as a valuable approach in bipolar depression (151), only non-benzodiazepine anxiolytics will be described.”
BackgroundWatson, S., Gallagher, P., Porter, R. J., Smith, M. S., Herron, L. J., Bulmer, S., Young, A. H., & Ferrier, I. N. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.029 · Cited by 145
Self-citationInflammatory mediators of cognitive impairment in bipolar disorder
Bauer, I. E., Pascoe, M. C., Wollenhaupt-Aguiar, B., Kapczinski, F., & Soares, J. C. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.04.017 · Cited by 135
“It is notable that in medicated BD patients the glucocorticoid receptor antagonist, mifepristone improves mood and spatial working memory, and to a lesser extent, verbal fluency and spatial recognition (Watson et al., 2012; Young et al., 2004).”
BackgroundHPA Axis Interactions with Behavioral Systems
Packard, A. E. B., Egan, A. E., & Ulrich‐Lai, Y. M. (2016) · Comprehensive physiology · doi:10.1002/cphy.c150042 · Cited by 151
Andrade, C., & Rao, N. K. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.74318 · Cited by 120
Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder
GALLAGHER, P., WATSON, S., SMITH, M., YOUNG, A., & FERRIER, I. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.020 · Cited by 129
“Page 5 of 23 glucocorticoid antagonists in schizophrenia and bipolar disorder, the results of which are reported elsewhere (Gallagher et al., 2005; Young et al., 2004).”
BackgroundInfluentialSelf-citationChengappa, K. N. R., Bowie, C. R., Schlicht, P. J., Fleet, D., Brar, J. S., & Jindal, R. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08413 · Cited by 120
Aas, M., Dazzan, P., Mondelli, V., Toulopoulou, T., Reichenberg, A., Di Forti, M., Fisher, H. L., Handley, R., Hepgul, N., Marques, T., et al. (2011) · Psychological Medicine · doi:10.1017/s0033291710001170 · Cited by 124
“Similar findings have been described in patients with schizophrenia (Walder et al. 2000 ; Halari et al. 2004) or bipolar disorder (Young et al. 2004).”
Marks, W. N., Fournier, N. M., & Kalynchuk, L. E. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.04.014 · Cited by 134
Childhood trauma and cognitive function in first-episode affective and non-affective psychosis
Aas, M., Dazzan, P., Fisher, H. L., Morgan, C., Morgan, K. D., Reichenberg, A., Zanelli, J., Fearon, P., Jones, P. B., Murray, R. M., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.03.017 · Cited by 140
“For example, both bipolar disorder and psychotic depressionhavebeenassociatedwith impaired cognitive function in the context of hyperactivity of the HPA axis, to a much larger extent than schizophrenia (Belanoff et al., 2001; Flores et al., 2006; Gallagher et al., 2005; Watson et al., 2004; Young et al., 2004).”
BackgroundThe receptor hypothesis and the pathogenesis of depression: Genetic bases and biological correlates
Wang, H., Wang, Z., & Chen, N. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105542 · Cited by 126
Wingenfeld, K., & Wolf, O. T. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00207.x · Cited by 113
“To our knowledge, only one study has investigated the impact of antiglucocorticoids on cognitive function in mood disorder [72].”
BackgroundYoung, A. H. (2004) · Stress · doi:10.1080/10253890500069189 · Cited by 111
“We hypothesized that treatment with the corticosteroid receptor antagonist RU-486 would improve neurocognitive functioning and attenuate depressive symptoms in bipolar depression (Watson et al. 2004, Young et al. 2004).”
BackgroundSelf-citationKrugers, H. J., Goltstein, P. M., Van Der Linden, S., & Joëls, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04842.x · Cited by 102
“However, in psychotic depression, brief treatment with RU486 was effective in reducing cognitive disturbances (although these cognitive effects of RU486 may be related, at least in part, to other brain regions like the prefrontal cortex; Belanoff et al., 2001, 2002; Young et al., 2004).”
BackgroundMethodInfluentialCentral role of glucocorticoid receptors in Alzheimer's disease and depression
Canet, G., Chevallier, N., Zussy, C., Desrumaux, C., & Givalois, L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00739 · Cited by 106
Hinkelmann, K., Moritz, S., Botzenhardt, J., Muhtz, C., Wiedemann, K., Kellner, M., & Otte, C. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.08.012 · Cited by 103
“And lastly, spatial working memory, verbal fluency, and spatial recognition memory improved in depressed bipolar patients after blocking the glucocorticoid receptor (Young et al., 2004).”
BackgroundDatson, N. A., Speksnijder, N., Mayer, J. L., Steenbergen, P. J., Korobko, O., Goeman, J., de Kloet, E. R., Joëls, M., & Lucassen, P. J. (2012) · Hippocampus · doi:10.1002/hipo.20905 · Cited by 100
“Hippocampus RU486 may be effective in enhancing cognition and mood (Young et al., 2004; Gallagher et al., 2009) but also in the treatment of psychosis in patients with psychotic major depression, although the results of clinical trials so far are not conclusive (Debattista et al., 2006; Carroll and…”
ResultNeuronal nitric oxide synthase and affective disorders
Zhou, Q., Zhu, X., Nemes, A. D., & Zhu, D. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.11.004 · Cited by 106
Spijker, A. T., & van Rossum, E. F. C. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04985.x · Cited by 102
Verbal fluency in bipolar disorders: A systematic review and meta-analysis
Raucher‐Chéné, D., Achim, A. M., Kaladjian, A., & Besche‐Richard, C. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.039 · Cited by 107
Miskowiak, K. W., Carvalho, A. F., Vieta, E., & Kessing, L. V. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.08.011 · Cited by 100
“Mifepristone Two RCTs investigated the effects of the corticosteroid receptor antagonist mifepristone based on evidence for negative effects of hyper-cortisolaemia on neurocognitive deficits in BD (Watson et al., 2012; Young et al., 2004).”
InfluentialBosscher, K. D., Craenenbroeck, K. V., Meijer, O. C., & Haegeman, G. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.076 · Cited by 106
The use of mifepristone in the treatment of neuropsychiatric disorders
DeBattista, C., & Belanoff, J. K. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.02.006 · Cited by 103
Wilkinson, P. O., & Goodyer, I. M. (2011) · Development and Psychopathology · doi:10.1017/s0954579411000472 · Cited by 86
Rimmele, U., Besedovsky, L., Lange, T., & Born, J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.254 · Cited by 92
“In line with this finding, a treatment with mifepristone over several days enhanced spatial working memory performance in humans with major depression, apart from benefiting mood in these patients (Belanoff et al, 2001; Young et al, 2004; Watson et al, 2012).”
ResultChronic non-invasive corticosterone administration abolishes the diurnal pattern of tph2 expression
Donner, N. C., Montoya, C. D., Lukkes, J. L., & Lowry, C. A. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.08.008 · Cited by 89
“In addition, our data provide further rationale for continued exploration of the use of HPA-axis-targeting medication for patients suffering from affective disorders (O'Dwyer et al., 1995; Belanoff et al., 2002; Pariante et al., 2003; Young et al., 2004).”
BackgroundProgesterone receptor modulators and the endometrium: changes and consequences†
Horne, F. M., & Blithe, D. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm023 · Cited by 98
“The antiglucocorticoid properties of mifepristone have provided a rationale for its use to treat neuropsychiatric disorders associated with abnormalities in the hypothalamic–pituitary axis (Wolkowitz and Reus, 1999; Belanoff et al., 2002; Pomara et al., 2002; Young et al., 2004; Simpson et al., 2005; Flores et al., 20…”
BackgroundAntiglucocorticoid treatments for mood disorders
Gallagher, P., Malik, N., Newham, J., Young, A. H., Ferrier, I. N., & Mackin, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005168.pub2 · Cited by 90
Self-citationRetractedWu, L., Han, H., Wang, Q., Hou, H., Tong, H., Yan, X., & Zhou, J. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301386 · Cited by 91
Wu, T.-C., Chen, H.-T., Chang, H.-Y., Yang, C., Hsiao, M., Cheng, M., & Chen, J. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.09.011 · Cited by 94
“, 1991), bipolar disorder (Young et al., 2004) and various neuropsychiatric disorders that plausibly relate to hyperactivity of HPA axis, in particular the psychotic depression (DeBattista and Belanoff, 2006).”
BackgroundEnvironmental enrichment exerts sex-specific effects on emotionality in C57BL/6J mice
Lin, E.-J. D., Choi, E., Liu, X., Martin, A., & During, M. J. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.08.019 · Cited by 80
“Polymorphisms in the GR gene have been found to correlate with the corticosteroid response to stress in both mice and human [64,65] and GR antagonists were shown to improve the mood of patients affected by either psychotic depression or bipolar disorder [3,66].”
BackgroundThe dex/CRH test—Is it better than the DST?
Watson, S., Gallagher, P., Smith, M. S., Ferrier, I. N., & Young, A. H. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2006.03.001 · Cited by 97
Self-citationSuccessful aging and the epidemiology of HIV
Vance, D. E., McGuinness, T. M., Musgrove, K., Orel, N. A., & Fazeli, P. L. (2011) · Clinical Interventions in Aging · doi:10.2147/cia.s14726 · Cited by 85
Havermans, R., Nicolson, N. A., Berkhof, J., & deVries, M. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.07.016 · Cited by 79
Selective increases in regional brain glucocorticoid: A novel effect of chronic alcohol
Little, H. J., Croft, A. P., O’Callaghan, M. J., Brooks, S. P., Wang, G., & Shaw, S. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.08.029 · Cited by 90
Cognitive Dysfunction in Bipolar Disorder: Future Place of Pharmacotherapy
Burdick, K. E., Braga, R. J., Goldberg, J. F., & Malhotra, A. K. (2007) · CNS Drugs · doi:10.2165/00023210-200721120-00002 · Cited by 102
Caraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014977 · Cited by 73
“Moreover, one 6-week pilot study found that 600 mg/day of mifepristone improved depressive symptoms and cognition in patients with treatment-resistant bipolar depression, and this clinically relevant improvement was inversely associated with basal cortisol levels (Young et al., 2004).”
BackgroundIndividual variability in the stress response of C57BL/6J male mice correlates with trait anxiety
Jakovcevski, M., Schachner, M., & Morellini, F. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00345.x · Cited by 74
“Moreover, patients with depression and anxiety disorders show dysregulation of GR function (Holsboer 2000; Korte 2001), and GR antagonists improve the mood of patients affected by either psychotic depression or bipolar disorder (Belanoff et al. 2002; Young et al. 2004).”
BackgroundBurdick, K. E., Braga, R. J., Nnadi, C. U., Shaya, Y., Stearns, W. H., & Malhotra, A. K. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07299 · Cited by 72
“The first was focused on the treatment of residual depressive symptoms in 20 bipolar patients using mifepristone (RU-486), a progesterone receptor antagonist (Young et al., 2004).”
Schüle, C., Baghai, T. C., Eser, D., & Rupprecht, R. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.52 · Cited by 73
The Management of Cognitive Impairment in Bipolar Disorder: Current Status and Perspectives
Sanches, M., Bauer, I. E., Galvez, J. F., Zunta‐Soares, G. B., & Soares, J. C. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000120 · Cited by 86
Taubenfeld, S. M., Riceberg, J. S., New, A. S., & Alberini, C. M. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.07.005 · Cited by 71
“In addition, it has been studied in clinical trials for treatment of psychotic depression (42-46), Alzheimer’s Disease (47-49), schizophrenia (50) and bipolar disorder (51).”
Wei, Q., Hebda-Bauer, E. K., Pletsch, A., Luo, J., Hoversten, M. T., Osetek, A. J., Evans, S. J., Watson, S. J., Seasholtz, A. F., & Akil, H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0910-07.2007 · Cited by 71
Self-citationSerotonin transporters: Implications for antidepressant drug development
White, K. J., Walline, C. C., & Barker, E. L. (2005) · The AAPS Journal · doi:10.1208/aapsj070242 · Cited by 83
Neurocognitive functioning in bipolar disorder: What we know and what we don’t
Keramatian, K., Torres, I. J., & Yatham, L. N. (2021) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2022.2042164 · Cited by 80
“Improvements in cognitive performance in bipolar depression was reported with erythropoietin (Miskowiak et al. 2014), mifepristone (Young et al. 2004; Watson et al. 2012) and creatine monohydrate (Toniolo et al. 2017).”
BackgroundThe role of mineralocorticoid receptor function in treatment-resistant depression
Juruena, M. F., Pariante, C. M., Papadopoulos, A. S., Poon, L., Lightman, S., & Cleare, A. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113499205 · Cited by 70
“The GR antagonist mifepristone (RU486) exerts therapeutic effects in the treatment of cognitive dysfunction in bipolar disorder (Young et al., 2004), but the data on core depressive symptoms in psychotic depression are less promising (Flores et al.”
BackgroundKamal, A., Ramakers, G. M. J., Altinbilek, B., & Kas, M. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.10.016 · Cited by 76
“…a study in human bipolar depression that showed that the GR antagonists RU 38486 had useful cognitive-enhancing and possibly antidepressant properties in bipolar disorder (Young et al., 2004), we showed that the LTP impairments in SI mice were rescued upon treatment with the GR antagonist RU 38486.”
Salagre, E., Solé, B., Tomioka, Y., Fernandes, B. S., Hidalgo-Mazzei, D., Garriga, M., Jimenez, E., Sanchez-Moreno, J., Vieta, E., & Grande, I. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.034 · Cited by 71
Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
Quiroz, J. A., Singh, J. B., Gould, T. D., Denicoff, K. D., Zarate, C. A., & Manji, H. K. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001521 · Cited by 75
Soria, V., González-Rodríguez, A., Huerta-Ramos, E., Usall, J., Cobo, J., Bioque, M., Barbero, J. D., García-Rizo, C., Tost, M., Monreal, J. A., et al. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.04.012 · Cited by 64
A preclinical and clinical rationale for quetiapine in mood syndromes
McIntyre, R. S., Soczynska, J. K., Woldeyohannes, H. O., Alsuwaidan, M. T., & Konarski, J. Z. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.9.1211 · Cited by 78
“Antiglucocorticoid treatment strategies have demonstrated antidepressant effects on mood and other psychiatric disorders [78,79].”
BackgroundFlux, M. C., & Lowry, C. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104578 · Cited by 65
Cholinergic modulation of dopamine pathways through nicotinic acetylcholine receptors
de Kloet, S. F., Mansvelder, H. D., & De Vries, T. J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.014 · Cited by 69
In vitro modulation of the glucocorticoid receptor by antidepressants
Carvalho, L. A., & Pariante, C. M. (2008) · Stress · doi:10.1080/10253890701850759 · Cited by 56
Cognition as a target in major depression: new developments.
Solé, B., Jiménez, E., Martinez-Aran, A., & Vieta, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.004 · Cited by 68
“Whereas in bipolar disorder there are studies with positive results (Young et al., 2004; Watson et al., 2012; Dias et al., 2012), no published studies have assessed the cognitive properties of mifepristone in major depressive samples.”
ResultNeurobiology of bipolar disorder
Newberg, A. R., Catapano, L. A., Zarate, C. A., & Manji, H. K. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.1.93 · Cited by 75
Abercrombie, H. C., Jahn, A. L., Davidson, R. J., Kern, S., Kirschbaum, C., & Halverson, J. L. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.10.005 · Cited by 68
“A number of studies have shown that both agonists and antagonists for corticosteroid receptors hold promise as therapeutic agents (DeBattista et al., 2000; Young et al., 2004; DeBattista and Belanoff, 2006; Otte et al., 2010).”
Metadata
- Authors
- Young, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M., & Nicol Ferrier, I.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Young, Allan H
- Venue
- Neuropsychopharmacology
- Published
- 2004-05-05
- Volume
- 29
- Issue
- 8
- Pages
- 1538-1545
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2041573038
- Cited by
- 318
- References
- 38
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 13 · 2023: 6 · 2022: 2 · 2021: 11 · 2020: 9 · 2019: 5 · 2018: 14 · 2017: 8 · 2016: 16 · 2015: 13 · 2014: 18 · 2013: 12 · 2012: 14
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Stanley Medical Research Institute
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- mifepristone, RU486, bipolar disorder, glucocorticoid receptor antagonist, hypercortisolism, neurocognitive function, spatial working memory, verbal fluency, spatial recognition memory, depressive symptoms, antidepressant effects, cognitive enhancement
- MeSH terms
- Adult, Affect, Attention, Bipolar Disorder, Cognition, Double-Blind Method, Female, Hormone Antagonists, Humans, Hydrocortisone, Learning, Male, Memory, Short-Term, Middle Aged, Psychiatric Status Rating Scales, Psychomotor Performance, Receptors, Glucocorticoid, Space Perception, Verbal Learning, Mifepristone, Treatment Outcome, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.